Literature DB >> 25702263

Surgery for isolated liver metastases from pancreatic cancer.

Nicola Zanini1, Raffaele Lombardi, Michele Masetti, Marco Giordano, Giovanni Landolfo, Elio Jovine.   

Abstract

The resection of liver metastases from pancreatic ductal adenocarcinoma has been discouraged because it is commonly thought that it does not improve survival. However, the role of potential prognostic factors is unclear, and universally accepted strategies have not been proposed. Between 2003 and 2014, 15 patients with isolated synchronous or metachronous metastases from pancreatic cancer underwent liver resection in our department. The role of potential prognostic factors was analyzed to predict survival. One right hepatectomy, 1 bisegmentectomy and 13 wedge resections were performed. Eleven patients underwent simultaneous pancreatic and liver resection for synchronous disease. The median overall survival (OS) was 9.1 months (95% CI 8.6-9.7). The only potential prognostic factor that significatively affected survival was the timing of metastases (metachronous vs. synchronous). Median OS in patients with metachronous disease was 11.4 months (95% CI 0-25.1) vs. 8.3 months (95% CI 6.9-9.7), p = 0.038. Surgery for liver metastases from pancreatic cancer is not suggested for most patients. If resection is considered, timing of metastatic disease could be a prognostic factor for survival after surgery.

Entities:  

Mesh:

Year:  2015        PMID: 25702263     DOI: 10.1007/s13304-015-0283-6

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  38 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

Authors:  Katia T Papalezova; Douglas S Tyler; Dan G Blazer; Bryan M Clary; Brian G Czito; Herbert I Hurwitz; Hope E Uronis; Theodore N Pappas; Christopher G Willett; Rebekah R White
Journal:  J Surg Oncol       Date:  2012-02-06       Impact factor: 3.454

3.  Surgery for recurrent pancreatic ductal adenocarcinoma.

Authors:  Jörg Kleeff; Carolin Reiser; Ulf Hinz; Jeannine Bachmann; Jürgen Debus; Dirk Jaeger; Helmut Friess; Markus W Büchler
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

4.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

5.  Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect.

Authors:  Dominique Elias; Gabriel Liberale; Déwi Vernerey; Marc Pocard; Michel Ducreux; Valérie Boige; David Malka; Jean-Pierre Pignon; Philippe Lasser
Journal:  Ann Surg Oncol       Date:  2005-09-26       Impact factor: 5.344

Review 6.  Hepatic resection for metastatic breast cancer: a systematic review.

Authors:  Terence C Chua; Akshat Saxena; Winston Liauw; Francis Chu; David L Morris
Journal:  Eur J Cancer       Date:  2011-07-07       Impact factor: 9.162

7.  A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer.

Authors:  Ioannis Hatzaras; Ana L Gleisner; Carlo Pulitano; Charbel Sandroussi; Kenzo Hirose; Omar Hyder; Christopher L Wolfgang; Luca Aldrighetti; Michael Crawford; Michael A Choti; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2012-05-31       Impact factor: 3.647

8.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

Authors:  Milena Sant; Claudia Allemani; Mariano Santaquilani; Arnold Knijn; Francesca Marchesi; Riccardo Capocaccia
Journal:  Eur J Cancer       Date:  2009-01-24       Impact factor: 9.162

9.  Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report.

Authors:  Tomonori Iida; Yukio Nakabayashi; Norimitsu Okui; Hiroaki Shiba; Masahiko Otsuka; Katsuhiko Yanaga
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

Review 10.  Resection of primary pancreatic cancer and liver metastasis: a systematic review.

Authors:  Christoph W Michalski; Mert Erkan; Norbert Hüser; Michael W Müller; Mark Hartel; Helmut Friess; Jörg Kleeff
Journal:  Dig Surg       Date:  2009-02-12       Impact factor: 2.588

View more
  13 in total

1.  Oligometastases of Gastrointestinal Cancer Origin.

Authors:  Ernst Klar; Markus W Büchler; Hauke Lang; Florian Lordick; Jens Mittler; Takashi Mizuno; Guido Torzilli; Alexis Ulrich; Jean-Nicolas Vauthey
Journal:  Visc Med       Date:  2017-02-28

2.  The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy.

Authors:  Emil Lou
Journal:  Ann Transl Med       Date:  2018-05

3.  Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study.

Authors:  Claire Decoster; Marine Gilabert; Aurélie Autret; Olivier Turrini; Sandrine Oziel-Taieb; Flora Poizat; Marc Giovannini; Patrice Viens; Juan Iovanna; Jean-Luc Raoul
Journal:  Oncotarget       Date:  2016-07-19

4.  Efficacy of transcatheter arterial chemoembolization for liver metastases arising from pancreatic cancer.

Authors:  Jun-Hui Sun; Tan-Yang Zhou; Yue-Lin Zhang; Guan-Hui Zhou; Chun-Hui Nie; Tong-Yin Zhu; Sheng-Qun Chen; Bao-Quan Wang; Song Ye; Yan Shen; Hua Guo; Wei-Lin Wang; Shu-Sen Zheng
Journal:  Oncotarget       Date:  2017-06-13

5.  Challenges in pancreatic adenocarcinoma surgery - National survey and current practice guidelines.

Authors:  Sameer A Dhayat; Philip Mirgorod; Christina Lenschow; Norbert Senninger; Christoph Anthoni; Thorsten Vowinkel
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

6.  Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases.

Authors:  Si Shi; Xian-Jun Yu
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

7.  Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1).

Authors:  Miaoyan Wei; Si Shi; Jie Hua; Jin Xu; Xianjun Yu
Journal:  BMJ Open       Date:  2019-12-08       Impact factor: 2.692

8.  Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis.

Authors:  Wentao Zhou; Dansong Wang; Wenhui Lou
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

9.  Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?

Authors:  Rachael Chang Lee; Harsh Kanhere; Markus Trochsler; Vy Broadbridge; Guy Maddern; Timothy J Price
Journal:  World J Gastrointest Oncol       Date:  2018-08-15

10.  Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology and End Results (SEER) Analysis.

Authors:  Lai Wang; Lina Yang; Lianyu Chen; Zhen Chen
Journal:  Med Sci Monit       Date:  2019-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.